Sunten Board Approves Fourth Buyback: NT$840 Million to Transfer Shares to Employees

Why did Sunten launch its fourth share buyback worth NT$840 million, and who will receive the shares?

Sunten's (晟德, TWSE: 4123) board resolved to buy back 20,000 board lots at NT$28–42 per share, transferring the shares to employees.CITE:E1CITE:E11

The board set the price range at NT$28 to NT$42 per share, capping the maximum outlay at NT$840 million.CITE:E2CITE:E10 The company also stated that if the share price falls below the lower end of that range, it will continue buying.CITE:E10 Sunten confirmed this is its fourth buyback program to date, and the stated purpose is to transfer the repurchased shares to employees.CITE:E11

Sunten posted a first-half loss of NT$11.24 per share — why is cash flow still positive, and why is it still paying a NT$2.25 dividend?

Sunten attributes the per-share loss to paper valuation swings, not operating performance, while cash generation stayed strong.CITE:E3CITE:E12

Sunten reported a first-half net loss of NT$11.24 per share, which it says mainly reflects capital-market volatility affecting the book value of its investment holdings rather than its actual operations.CITE:E3CITE:E12 Despite that headline loss, the company recorded cumulative net cash inflow of NT$3.29 billion for the first half, which it described as the key support behind launching the buyback.CITE:E4CITE:E13 Separately, Sunten's board decided to distribute a cash dividend of NT$1.75 per share plus a stock dividend of NT$0.5 per share, for a combined NT$2.25, with the stock going ex-rights and ex-dividend on August 17, 2026.CITE:E9CITE:E14

What returns has Sunten generated for investors since converting to a holding company in 2008?

Sunten says its total-return calculation shows more than sixfold cumulative gains for investors since converting to a holding company in 2008.CITE:E5CITE:E15

By the company's own accounting, using a total-return method that restores the value of dividends and rights, Sunten has generated cumulative investment returns exceeding six times the original value for investors since its 2008 transition to a holding-company structure.CITE:E5CITE:E15

How are Sunten's portfolio companies progressing?

Sunten's core holdings show four distinct milestones: two nearing global licensing, one advancing pivotal trials, and two posting multiple-fold revenue growth.CITE:E16

According to Sunten, 益安生醫 (ticker 6499) and 博晟生醫 (ticker 6733) have moved their self-developed, high-end products into the global licensing stage.CITE:E6CITE:E16 順藥 (ticker 6535) is advancing a Phase 2-bridging-Phase 3 clinical trial in China.CITE:E7CITE:E16 Meanwhile, 永昕生醫 (ticker 4726) and 豐華生技 have posted revenue described as growing by multiples, which Sunten calls an important growth driver for its investment portfolio going forward.CITE:E8CITE:E16

Key figures at a glance

What does this mean?

The reported figures sit side by side without contradiction: a first-half per-share loss of NT$11.24 driven by investment-book valuation swings coexists with NT$3.29 billion in net cash inflow, which Sunten cites as the funding basis for both the NT$840 million buyback and the NT$2.25 combined dividend going ex-rights on August 17.CITE:E3CITE:E4CITE:E9 Sunten frames the fourth buyback and the employee share transfer against a longer backdrop — a claimed sixfold cumulative return since its 2008 holding-company conversion and progress across its portfolio, from licensing-stage products at 益安生醫 and 博晟生醫 to a bridging trial at 順藥 and multiple-fold revenue growth at 永昕生醫 and 豐華生技.CITE:E5CITE:E6CITE:E7CITE:E8